OFELIA: Prevalence of Osteoporosis in Fragility Fracture Patients
- 218 Downloads
Abstract
Worldwide, a care gap has been recognized between presenting with a fracture and prevention of the next fracture. Fracture Liaison Service is the most cost-effective method to close this gap, but its implementation is sparse in the Nordic countries. To assess the need for a fracture prevention program, the primary aim of this study was to estimate the prevalence of osteoporosis in patients treated for fragility fractures at Aarhus University Hospital, Denmark. Secondary aims were to identify clinical risk factors associated with osteoporosis and the up-take of anti-osteoporosis treatment. The study was conducted as a cross-sectional study and patients aged 18+ years were consecutively identified over a 12 months period. Of 1164 identified patients, 832 were included and 794 (70% women, 66% aged ≥ 50 years) patients completed the study. Bone mineral density was measured by DXA and information about clinical risk factors were obtained. The overall prevalence of osteoporosis in this cohort was 14.9%, increasing to 20.3% in patients ≥ 50 years (22.9% in women, 9.6% in men). In addition to age above 50 years, female sex, low BMI, and early menopause were significantly associated with osteoporosis. At 3-years follow-up in patients diagnosed with osteoporosis, 95% of patients who initiated anti-osteoporosis treatment after their fracture were still adherent to treatment. Given that osteoporosis was demonstrated in one in five fragility fracture patients above 50 years, OFELIA stresses the need for implementation of a program aiming at securing appropriate investigation and treatment of osteoporosis in patients presenting a fragility fracture.
Keywords
Osteoporosis Secondary fracture prevention Fracture risk assessment ScreeningNotes
Acknowledgements
We wish to express our gratitude to all participants in OFELIA for their willingness to make this study possible. To our colleagues at the Department of orthopedic surgery (E) and the Department emergency and acute medicine (FAA) at Aarhus University Hospital (AUH) for identifying fracture patients for this study. Also, many thanks to the staff at The Osteoporosis Clinic, AUH for their great work performing the DXAs.
Author Contributions
Study design and conduct: RT, BL and OB. Data collection: RT. Data analysis and interpretation: RT, CR, OR, OB and BL. Drafting manuscript: RT and BL. Revising manuscript content: CR, OR and OB. Approving final version of manuscript: RT, CH, OR, OB and BL. RT takes responsibility for the integrity of the data analysis, has full control of all primary data and agrees to allow the journal to review data if requested.
Funding
For financial support, we wish to thank the Health Research Fund of Central Denmark Region, Aarhus University Hospital (“Spydspidspuljen”), Department of Endocrinology and Internal Medicine (MEA), AUH and the Danish Osteoporosis Society.
Compliance with Ethical Standards
Conflict of interest
Bente L. Langdahl has received honoraria for consulting and lecturing for Amgen, Merck, UCB, and TEVA and received research grants from Amgen and Novo Nordisk. Randi M. H. Tei, Cecilia H. Ramlau-Hansen, Oleguer Plana-Ripoll, Ole Brink have no conflicts of interests.
Ethical Approval
The study complies with the principles outlined in the Declaration of Helsinki. The study was approved by the Danish Data Protection Agency.
Informed Consent
All informants were informed that they could withdraw their participation at any time before or during the interview without any consequences for their further fracture treatment and follow-up. The study was approved by the Danish Data Protection Agency (J. No. 2007-58-0016). We submitted the protocol to review by the Central Denmark Region Committees on Health Research Ethics, but they found that the study procedures were in accordance to the Danish osteoporosis guidelines and non-interventional. Therefore, the study did not need formal ethical approval and did not need informant consent. Nevertheless, in agreement with good clinical practice we collected informed written consent from all participants.
Supplementary material
References
- 1.[Anonymous] (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650CrossRefGoogle Scholar
- 2.Center J, Eisman J (1997) The epidemiology and pathogenesis of osteoporosis. Baillière’s Clin Endocrinol Metab 11:23–62CrossRefGoogle Scholar
- 3.Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936CrossRefGoogle Scholar
- 4.Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, Eisman JA, March L, Seibel MJ (2013) Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int 24:393–406CrossRefGoogle Scholar
- 5.McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision (structured abstract). Osteoporos Int 22:2083–2098CrossRefGoogle Scholar
- 6.Mehrpour SR, Aghamirsalim MR, Sorbi R (2012) Are hospitalized patients with fragile fractures managed properly in relation to underlying osteoporosis? J Clin Rheumatol 18:122–124CrossRefGoogle Scholar
- 7.Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778CrossRefGoogle Scholar
- 8.Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35:293–305CrossRefGoogle Scholar
- 9.McCloskey EV, Harvey NC, Kanis JA (2015) Can we treat to target in osteoporosis?. Int J Clin Rheumatol 10:01CrossRefGoogle Scholar
- 10.Boonen S, Reginster J, Kaufman J, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714–1723CrossRefGoogle Scholar
- 11.Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefGoogle Scholar
- 12.Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefGoogle Scholar
- 13.Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefGoogle Scholar
- 14.Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541CrossRefGoogle Scholar
- 15.Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH (2018) Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies. Bone 116:58–66CrossRefGoogle Scholar
- 16.Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739CrossRefGoogle Scholar
- 17.Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382CrossRefGoogle Scholar
- 18.Wu C-, Kao I-, Hung W-, Lin S-, Liu H-, Hsieh M-, Bagga S, Achra M, Cheng T, Yang R (2018) Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature. Osteoporos Int 29:1227–1242CrossRefGoogle Scholar
- 19.Marsh D, Åkesson K, Beaton DE, Bogoch ER, Boonen S, Brandi M-, McLellan AR, Mitchell PJ, Sale JEM, Wahl DA (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051–2065CrossRefGoogle Scholar
- 20.McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028–1034CrossRefGoogle Scholar
- 21.United Kingdom, National Osteoporosis Society. http://www.nos.org.uk. Accessed 31 Aug 2018
- 22.van Geel TACM, Bliuc D, Geusens PPM, Center JR, Dinant G, Tran T, van den Bergh JPW, McLellan AR, Eisman JA (2018) Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: a prospective cohort study. PLoS ONE 13(6):e0198006CrossRefGoogle Scholar
- 23.Mitchell PJ (2013) Best practices in secondary fracture prevention: fracture liaison services. Curr Osteoporos Rep 11:52–60CrossRefGoogle Scholar
- 24.Åkesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C (2013) Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152CrossRefGoogle Scholar
- 25.Leslie WD, Giangregorio LM, Yogendran M, Azimaee M, Morin S, Metge C, Caetano P, Lix LM (2012) A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving. Osteoporos Int 23(5):1623–1629CrossRefGoogle Scholar
- 26.Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27:2039–2046CrossRefGoogle Scholar
- 27.Hansen L, Petersen KD, Eriksen SA, Langdahl BL, Eiken PA, Brixen K, Abrahamsen B, Jensen JB, Harsløf T, Vestergaard P (2015) Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. Osteoporos Int 26(2):513–519CrossRefGoogle Scholar
- 28.Bliuc D, Ong CR, Eisman JA, Center JR (2005) Barriers to effective management of osteoporosis in moderate and minimal trauma fractures: a prospective study. Osteoporos Int 16:977–982CrossRefGoogle Scholar
- 29.Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30:1747–1753CrossRefGoogle Scholar
- 30.Fracture risk assessment tool FRAX. http://www.shef.ac.uk/FRAX. Accessed 31 Aug 2018
- 31.Vestergaard P, Rejnmark L, Mosekilde L (2006) Socioeconomic aspects of fractures within universal public healthcare: a nationwide case-control study from Denmark. Scand J Public Health 34:371–377CrossRefGoogle Scholar
- 32.Pedersen MA, Gregersen M, Langdahl BL, Damsgaard EMS (2014) Frail elderly hip fracture patients and vitamin D. J Gerontol Geriatr Res 3(5):180Google Scholar
- 33.Abrahamsen B, Vestergaard P (2010) Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006. Osteoporos Int 21:373–380CrossRefGoogle Scholar
- 34.Clunie G, Stephenson S (2008) Implementing and running a fracture liaison service: an integrated clinical service providing a comprehensive bone health assessment at the point of fracture management. J Orthop Nurs 12:159–165CrossRefGoogle Scholar
- 35.Osteoporosis Canada. http://www.osteoporosis.ca. Accessed 31 Aug 2018
- 36.Löffman O, Hallberg I, Berglund K, Wahlström O, Kartous L, Rosenqvist AM, Larsson L, Toss G (2007) Women with low-energy fracture should be investigated for osteoporosis. Acta Orthop 78:813–821CrossRefGoogle Scholar
- 37.Åstrand J, Thorngren KG, Tägil M (2006) One fracture is enough!: experience with a prospective and consecutive osteoporosis screening program with 239 fracture patients. Acta Orthop 77:3–8CrossRefGoogle Scholar
- 38.Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment. JAMA 286:2815–2822CrossRefGoogle Scholar
- 39.Svejme O, Ahlborg H, Nilsson J, Karlsson M (2012) Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women. BJOG: Int J Obstet Gynaecol 119:810–816CrossRefGoogle Scholar
- 40.Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefGoogle Scholar
- 41.Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018CrossRefGoogle Scholar
- 42.De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HAP, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338CrossRefGoogle Scholar
- 43.Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411CrossRefGoogle Scholar
- 44.Eekman DA, van Helden SH, Huisman AM, Verhaar HJJ, Bultink IEM, Geusens PP, Lips P, Lems WF (2014) Optimizing fracture prevention: the fracture liaison service, an observational study. Osteoporos Int 25:701–709CrossRefGoogle Scholar
- 45.Langdahl BL (2017) Osteoporosis in premenopausal women. Curr Opin Rheumatol 29:410–415CrossRefGoogle Scholar
- 46.Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571–581CrossRefGoogle Scholar
- 47.Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501CrossRefGoogle Scholar
- 48.Huas D, Debiais F, Blotman F, Cortet B, Mercier F, Rousseaux C, Berger V, Gaudin A, Cotté F (2010) Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Womens Health 10:26CrossRefGoogle Scholar